Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (460)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06496815 | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | not yet recruiting | Phase 4 | 32 | Tongji HospitalOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06138769 | Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma | active not recruiting | Phase 2 | 50 | Asan Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06482801 | Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT | recruiting | Phase 2 | 90 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06478927 | Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib | recruiting | N/A | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03949231 | Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma | recruiting | Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04952272 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | recruiting | Phase 1 | 50 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03198546 | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06470256 | Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Zhiyong HuangOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04340986 | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma(CHC/CC) | recruiting | — | 1,250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06449846 | Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma | not yet recruiting | — | 152 | Zhujiang HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06204835 | ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery | recruiting | Phase 1 | 90 | Institute of Automation, Chinese Academy of SciencesOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06418165 | Vienna Hypothermic Oxygenated Machine Perfusion Study(VIHOMPS) | recruiting | — | 500 | Medical University of ViennaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05866783 | Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma(GLITCA) | recruiting | — | 500 | University Hospital, GhentOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06409637 | FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation | not yet recruiting | Phase 1 / Phase 2 | 62 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06406244 | Efficacy of TEAS on Chronic Pain and Survival in Patients Undergoing Hepatectomy | recruiting | N/A | 524 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06406634 | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06397222 | Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC | recruiting | Phase 2 | 23 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06398028 | The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound. | recruiting | Phase 4 | 173 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06089369 | Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | not yet recruiting | Phase 3 | 360 | Tongji HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06389422 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05738616 | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | recruiting | Phase 3 | 196 | Wen TianfuOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06257030 | The AMARA (As Much As Reasonably Achievable) Study | recruiting | — | 100 | University Hospital of PatrasOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06379334 | Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population | active not recruiting | — | 180 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | recruiting | Phase 2 | 111 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06375317 | HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure | not yet recruiting | Phase 2 | 42 | Yehua ShenOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363825 | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 57 | Fujian Medical UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06364787 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT05714124 | Liver Embolization Approaches for Tumor Management(LEATUM) | recruiting | — | 580 | IRCCS San RaffaeleOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06363006 | Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer | recruiting | Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06241326 | Immunotherapy for Hepatocellular Carcinoma(IFHC) | recruiting | — | 11,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05652920 | Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | recruiting | Phase 1 / Phase 2 | 105 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06326502 | A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Etnova Therapeutics Corp.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06331260 | Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 600 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06331273 | Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 800 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06317896 | Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS | not yet recruiting | — | 82 | Zhujiang HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06315361 | DIAbetes and NAFLD(DIANA) | active not recruiting | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06313554 | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | N/A | 63 | Fudan UniversityOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06261125 | Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)(HSBRT2401) | recruiting | Phase 2 | 60 | Mian XIOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06253598 | Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT05970666 | Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 71 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 11, 2024source: clinicaltrials